TY - JOUR
T1 - From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies
AU - Caruana, Ignazio
AU - Diaconu, Iulia
AU - Dotti, Gianpietro
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise review article, we will summarize the application of antibodies designed to target antigens expressed by tumor cells, and the transition from these antibodies to the generation of CARs.
AB - Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise review article, we will summarize the application of antibodies designed to target antigens expressed by tumor cells, and the transition from these antibodies to the generation of CARs.
UR - http://www.scopus.com/inward/record.url?scp=84909629962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84909629962&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2014.08.005
DO - 10.1053/j.seminoncol.2014.08.005
M3 - Article
C2 - 25440610
AN - SCOPUS:84909629962
SN - 0093-7754
VL - 41
SP - 661
EP - 666
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 5
ER -